Additional Details
-
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Duke University Medical CenterDurham NC. 27705 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Dignity Health Norton Thoracic InstitutePhoenix AZ. 85013 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Lowcountry Lung and Critical CareCharleston SC. 29406 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Pulmonary Associates, PAMesa AZ. 85206-1346 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
The Lung Research Center, LLCChesterfield MO. 63017 -
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
University of Kansas Medical Center Research Institute, IncKansas City KS. 66160 -
FAPI PET for Lung Fibrosis
UCLA / Jonsson Comprehensive Cancer CenterLos Angeles CA. 90095 -
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
University Health Network Toronto General HospitalToronto ON. M5G 2N2 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
UCLA Health Westwood Medical PlazaWestwood CA. 90095 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
National Jewish Health Medical Center ( Site 4015)Denver CO. 80206 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
University of Michigan Hospital ( Site 4001)Ann Arbor MI. 48109 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Rutgers Robert Wood Johnson Medical School ( Site 4013)New Brunswick NJ. 08901 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
UT Physicians Rheumatology ( Site 4007)Houston TX. 77030 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
St. Joseph's Health Care London ( Site 4701)London ON. N6A 4V2 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
MedStar Georgetown University Hospital ( Site 4005)Washington DC. 20007 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Medical University of South Carolina - PPDS ( Site 4004)Charleston SC. 29425 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Stanford Health Care ( Site 4009)Palo Alto CA. 94304 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Cedars Sinai Medical Center ( Site 4010)Los Angeles CA. 90048 -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Boston University School of Medicine ( Site 4021)Boston MA. 02118